More Information on 'TaKaRa Bio Inc'

Takara Bio Inc. is a Japanese biotechnology company that operates in several key areas. The company's core business includes the development and supply of research reagents, scientific instruments, and contract development and manufacturing organization (CDMO) services. Additionally, Takara Bio is involved in the development and manufacturing of gene therapies, as evidenced by the recent marketing authorization approvals for Waskyra, a gene therapy product. The company aims to contribute to the development of the life science industry and improve human health through its various business segments, positioning itself as a global platform provider for the industry's infrastructure.

About TaKaRa Bio Inc
Since its beginnings as the biomedical business of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.), Takara Bio has continuously expanded its gene and DNA-related businesses, which have now developed into three business segments. In 1979, the Genetic engineering research business was launched with the sale of the first domestically produced restriction enzymes. This business has now expanded to include a portfolio of genetic engineering research reagents, scientific instruments and contract research services that are essential to biotechnology researchers worldwide. In the AgriBio segment, which was the first to succeed in the large-scale production of Bunashimeji mushrooms in 1970, we promote a business centered on technologies for the large-scale production of mushrooms, including the production and sale of Hatakeshimeji and Honshimeji mushrooms. We also offer customers food materials such as Gagome kombu (kelp) "fucoidan" agar "agaro-oligosaccharide" and Ashitaba (angelica herb) "chalcone" whose functionality has been proven through the use of biotechnology. In the Gene medicine segment, we are pursuing the development and commercialization of cutting-edge medical technologies, such as cell and gene therapies for cancer and AIDS, based on technologies developed and accumulated through the activities of our Genetic engineering research segment. Our business strategy is to invest the stable income generated by the Genetic engineering research and AgriBio segments into the Gene medicine segment in order to develop gene medicine technologies, thereby expanding our future earnings. Takara Bio Inc. contributes to the health of mankind by making revolutionary biomedical technology, such as gene therapy, a reality.